Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

100022

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patient Choice Schemes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to promote patient choice.
tabling member constituency	Stroud
tabling member printed	Neil Carmichael
uin	905559
answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 16:00:56 answering member 4020 label Biography information for George Freeman
tabling member	4104 label Biography information for Neil Carmichael

100186

registered interest
date	21/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patients: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	211233
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 15:28:25 question first ministerially corrected 28/10/2014 16:30:53 answering member 4020 label Biography information for George Freeman previous answer version 24770 answering member constituency Battersea answering member printed Jane Ellison answering member 3918
tabling member	95 label Biography information for Mr Andrew Smith

100402

registered interest
date	22/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Paralysis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he has taken to support University College London in its work to enable people who have been paralysed to regain the ability to walk.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	211576
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The Department’s National Institute for Health Research (NIHR) funds 11 biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2014 16:53:22 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

100411

registered interest
date	22/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cystic Fibrosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	211584
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2014 16:52:12 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

100816

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance his Department has issued to health technology appraisal committees on application of NICE's end of life criteria when appraising treatments for patients with terminal illness.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	211809
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:56:20 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

100817

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what rationale lies behind NICE's advice that end-of-life criteria should only apply to medicines that extend life by at least three months.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	211807
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued supplementary advice to its appraisal committees on appraising treatments which may be life-extending for patients, with short life expectancy, and which are licensed for indications affecting small numbers of patients with incurable illnesses.</p><p> </p><p> </p><p> </p><p>This sets out the following three criteria that must all be satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment is indicated for patients with a short life expectancy, normally less than 24 months;</p><p> </p><p>- there is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional three months, compared to current NHS treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed following public consultation and set out the circumstances when NICE considers it is appropriate for its appraisal committees to apply greater flexibility in their appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making" target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:27:08 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

65962

registered interest
date	07/07/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Life Sciences: Northern Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what work the Life Science Investment Organisation is doing to promote the life sciences sector in Northern Ireland.
tabling member constituency	Bury South
tabling member printed	Mr Ivan Lewis
uin	204143
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>The Life Sciences Organisation (LSO) (previously the Life Sciences Investment Organisation, which now includes responsibility for UK trade promotion) works to promote the UK Life Sciences sector as a whole. LSO works closely with Invest Northern Ireland, along with the other devolved bodies and local enterprise partnerships across England, to understand the nation’s internationally competitive commercial offers in life sciences. We then actively market these strengths using our international network of investment advisors and suite of promotional materials. Where potential investors have specifically stated particular requirements, we will match these to the various regional offers and bring these out clearly in the tailored proposition materials produced for the investors.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/07/2014 14:48:34 answering member 4020 label Biography information for George Freeman
tabling member	441 label Biography information for Mr Ivan Lewis

77653

registered interest
date	14/07/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Manufacturing Industries: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what steps his Department is taking to encourage international pharmaceutical companies to locate in the UK.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	205633
answer	answer is ministerial correction date of answer 28/08/2014 answer text <p>In December 2011, the Government launched the Strategy for UK Life Sciences which includes measures to improve the commercial, research and regulatory environment, with the aim of making the UK the location of choice for investment. Government has also taken steps to strengthen protection for intellectual property in the UK.</p><p>In 2012 a specific organisation was set up to promote life sciences to international companies: the Life Sciences Investment Organisation (now reformed as the Life Sciences Organisation (LSO), with responsibility also for UK trade promotion). LSO collects and distils information on the UK’s internationally competitive commercial offers in life sciences; these are marketed to potential investors via the UK Trade and Investment global network of investment advisors, with tailored support provided to those investors that choose the UK.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/08/2014 15:54:58 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

78736

registered interest
date	17/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Bexsero vaccine is licensed for (a) individual application and (b) use in conjunction with other vaccines.
tabling member constituency	The Cotswolds
tabling member printed	Geoffrey Clifton-Brown
uin	206537
answer	answer is ministerial correction date of answer 02/09/2014 answer text <p>Bexsero, a Meningococcal group B vaccine, was licenced for the active immunisation of individuals from two months of age and older against invasive meningococcal disease caused by <em>Neisseria meningitidis</em> group B. It can be administered individually or concomitantly with a number of other vaccine antigens, either as monovalent or as combination vaccines such as diphtheria, tetanus, acellular pertussis, <em>Haemophilus influenzae </em> type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, and varicella. When given concomitantly with other vaccines Bexsero must be administered at a separate injection site.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/09/2014 13:40:37 answering member 4020 label Biography information for George Freeman
tabling member	249 label Biography information for Sir Geoffrey Clifton-Brown

78909

registered interest
date	18/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents of medication errors involving hospital patients with Parkinson's disease have been reported since the joint patient safety alert on steps to improve data reporting quality was issued by NHS England and the Medicines and Healthcare Products Regulatory Agency in March 2014.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	206600
answer	answer is ministerial correction date of answer 03/09/2014 answer text <p>NHS England has advised that, between 20 March 2014 and 21 July 2014, 617 incidents in general, acute or community hospitals or mental health facilities involving Parkinson’s disease and medicines used to treat Parkinson’s disease were reported through the National Reporting and Learning System.</p><p>Improving services for people with Parkinson's disease and other neurological conditions is a key priority for NHS England. Its strategic clinical networks have a specific focus on patients with neurological problems, such as Parkinson’s disease. NHS trusts and care homes in England should have policies and procedures in place to ensure that people with Parkinson’s disease receive their medicines when they are required to take them to control their illness and symptoms.</p><p>NHS England has recently launched a medication ‘safety thermometer’ that enables health and care organisations to measure aspects of medication safety on a regular basis for improvement purposes. This will enable hospitals to track their progress in reducing the number of omitted doses of medicines, including of those used to treat Parkinson’s disease.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 206629 question first answered 03/09/2014 09:44:33 answering member 4020 label Biography information for George Freeman
tabling member	4125 label Biography information for Catherine McKinnell